The final analysis confirms that next-generation obesity therapies, including Cagrilintide and Tirzepatide, exhibit strong, reproducible efficacy, with no remaining scientific conflicts. As evidence mounts supporting their role in significant weight loss and diabetes prevention, stakeholders are poised to finalize communication on these findings, paving the way for broader implementation in clinical settings.